



Steven Fong

Professor of Pathology, Emeritus

CONTACT INFORMATION

- **Alternate Contact**

Bri Stark She/Her - Administrative Associate

Email bristark@stanford.edu

Tel 650-721-1845

Bio

ACADEMIC APPOINTMENTS

- Emeritus Faculty, Acad Council, Pathology

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

The focus of the Fong Laboratory is to define immune correlates of protection against hepatitis C virus and other viral pathogens. More specifically, our goal is to define protective humoral immunity to viral pathogens through the isolation, biochemical and functional characterization of broadly neutralizing human or nonhuman primate monoclonal antibodies. Dependent on the pathogen, approaches to isolate these antibodies include yeast surface IgG display or single-cell cloning. These efforts will create high-resolution, functional maps of linear and nonlinear epitopes comprising the major binding sites of both isolate-specific and broadly neutralizing antibodies for rational vaccine design.

Publications

PUBLICATIONS

- **Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independent.** *The Journal of general virology*
Mimms, J. L., Sinnis-Bourozikas, A., Felbinger, N. R., Frumento, N., Paul, H. T., Patel, A. H., Keck, Z., Fong, S. K., Law, M., Urbanowicz, R. A., Tarr, A. W., Ball, J. K., Pierce, et al
2026; 107 (1)
- **Cryo-EM structures of HCV E2 glycoprotein bound to neutralizing and non-neutralizing antibodies determined using bivalent Fabs as fiducial markers.** *Communications biology*
Shahid, S., Karade, S. S., Hasan, S. S., Yin, R., Jiang, L., Liu, Y., Felbinger, N., Kulakova, L., Toth, E. A., Keck, Z. Y., Fong, S. K., Fuerst, T. R., Pierce, et al
2025; 8 (1): 825
- **An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection.** *Nature communications*
Mukherji, A., Jühling, F., Simanjuntak, Y., Crouchet, E., Del Zompo, F., Teraoka, Y., Haller, A., Baltzinger, P., Paritala, S., Rasha, F., Fujiwara, N., Gadenne, C., Slovic, et al
2024; 15 (1): 7486

- **Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.** *Journal of hepatology*
Kundu, J., Le, H. T., Logan, M., Hockman, D., Landi, A., Crawford, K., Winingar, M., Johnson, J., Kundu, J. K., Tiffney, E. A., Urbanowicz, R. A., Ball, J. K., Bailey, et al
2024
- **Hepatitis E virus seropositivity in an ethnically diverse community blood donor population.** *Vox sanguinis*
Mah, J. K., Keck, M., Chu, D. Y., Sooryanarain, H., Sahoo, M. K., Lau, P., Huang, C., Weber, J., Belanger, G. A., Keck, Z., Shan, H., Meng, X., Foug, et al
2023
- **Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate.** *Proceedings of the National Academy of Sciences of the United States of America*
Wang, R., Suzuki, S., Guest, J. D., Heller, B., Almeda, M., Andrianov, A. K., Marin, A., Mariuzza, R. A., Keck, Z. Y., Foug, S. K., Yunus, A. S., Pierce, B. G., Toth, et al
2022; 119 (11): e2112008119
- **Editorial overview: Engineering elimination of chronic viral hepatitis.** *Current opinion in virology*
Walker, C., Ou, J., Foug, S.
2021; 52: 57-59
- **An antigenically diverse, representative panel of envelope glycoproteins for HCV vaccine development.** *Gastroenterology*
Salas, J. H., Urbanowicz, R. A., Guest, J. D., Frumento, N., Figueroa, A., Clark, K. E., Keck, Z., Cowton, V. M., Cole, S. J., Patel, A. H., Fuerst, T. R., Drummer, H. E., Major, et al
2021
- **Structural perspectives on HCV humoral immune evasion mechanisms.** *Current opinion in virology*
Sevvana, M., Keck, Z., Foug, S. K., Kuhn, R. J.
2021; 49: 92-101
- **Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.** *Proceedings of the National Academy of Sciences of the United States of America*
Guest, J. D., Wang, R. n., Elkholy, K. H., Chagas, A. n., Chao, K. L., Cleveland, T. E., Kim, Y. C., Keck, Z. Y., Marin, A. n., Yunus, A. S., Mariuzza, R. A., Andrianov, A. K., Toth, et al
2021; 118 (3)
- **Crystal Structure of a Bivalent Antibody Fab Fragment.** *Journal of molecular biology*
Shahid, S., Gao, M., Travis Gallagher, D., Pozharski, E., Brinson, R. G., Keck, Z., Foug, S. K., Fuerst, T. R., Mariuzza, R. A.
2020
- **Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization.** *Journal of virology*
Pierce, B. G., Keck, Z., Wang, R., Lau, P., Garagusi, K., Elkholy, K., Toth, E. A., Urbanowicz, R. A., Guest, J. D., Agnihotri, P., Kerzic, M. C., Marin, A., Andrianov, et al
2020
- **An alternate conformation of HCV E2 neutralizing face as an additional vaccine target** *SCIENCE ADVANCES*
Tzarum, N., Giang, E., Kadam, R. U., Chen, F., Nagy, K., Augestad, E. H., Velazquez-Moctezuma, R., Keck, Z., Hua, Y., Stanfield, R. L., Dreux, M., Prentoe, J., Foug, et al
2020; 6 (30): eabb5642
- **SARS-CoV-2 RNAemia in a Healthy Blood Donor 40 Days After Respiratory Illness Resolution.** *Annals of internal medicine*
Pham, T. D., Huang, C. n., Wirz, O. F., Röltgen, K. n., Sahoo, M. K., Layon, A. n., Pandey, S. n., Foug, S. K., Boyd, S. D., Pinsky, B. A.
2020
- **Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection** *HEPATOLOGY*
Wrensch, F., Ligat, G., Heydmann, L., Schuster, C., Zeisel, M. B., Pessaux, P., Habersetzer, F., King, B. J., Tarr, A. W., Ball, J. K., Winkler, M., Poehlmann, S., Keck, et al
2019; 70 (5): 1506–20
- **Learning from a clinical cohort for HCV vaccine development** *JOURNAL OF HEPATOLOGY*
Wrensch, F., Keck, Z., Foug, S. K. H., Baumert, T. F.
2019; 71 (1): 9–11

- **Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.** *PLoS pathogens*
Keck, Z., Pierce, B. G., Lau, P., Lu, J., Wang, Y., Underwood, A., Bull, R. A., Prentoe, J., Velazquez-Moctezuma, R., Walker, M. R., Luciani, F., Guest, J. D., Fauvelle, et al
2019; 15 (5): e1007772
- **IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection.** *Hepatology (Baltimore, Md.)*
Wrensch, F., Ligat, G., Heydmann, L., Schuster, C., Zeisel, M. B., Pessaux, P., Habersetzer, F., King, B. J., Tarr, A. W., Ball, J. K., Winkler, M., Pohlmann, S., Keck, et al
2019
- **Learning from a clinical cohort for HCV vaccine development.** *Journal of hepatology*
Wrensch, F., Keck, Z., Foug, S. K., Baumert, T. F.
2019
- **Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells** *JOURNAL OF VIROLOGY*
Urbanowicz, R. A., Wang, R., Schiel, J. E., Keck, Z., Kerzic, M. C., Lau, P., Rangarajan, S., Garagusi, K. J., Tan, L., Guest, J. D., Ball, J. K., Pierce, B. G., Mariuzza, et al
2019; 93 (7)
- **In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection** *ANTIVIRAL RESEARCH*
Mailly, L., Wrensch, F., Heydmann, L., Fauvelle, C., Brignon, N., Zeisel, M. B., Pessaux, P., Keck, Z., Schuster, C., Fuerst, T. R., Foug, S. K. H., Baumert, T. F.
2019; 162: 136–41
- **Antigenicity and Immunogenicity of Differentially Glycosylated HCV E2 Envelope Proteins Expressed in Mammalian and Insect Cells.** *Journal of virology*
Urbanowicz, R. A., Wang, R., Schiel, J. E., Keck, Z., Kerzic, M. C., Lau, P., Rangarajan, S., Garagusi, K. J., Tan, L., Guest, J. D., Ball, J. K., Pierce, B. G., Mariuzza, et al
2019
- **Isolation of HCV Neutralizing Antibodies by Yeast Display.** *Methods in molecular biology (Clifton, N.J.)*
Keck, Z., Wang, Y., Lau, P., Foug, S. K.
2019; 1911: 395–419
- **Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp)** *HEPATITIS C VIRUS PROTOCOLS*
Bailey, J. R., Urbanowicz, R. A., Ball, J. K., Law, M., Foug, S. K. H.
edited by Law, M.
2019; 1911: 441-450
- **Isolation of HCV Neutralizing Antibodies by Yeast Display** *HEPATITIS C VIRUS PROTOCOLS*
Keck, Z., Wang, Y., Lau, P., Foug, S. K. H.
edited by Law, M.
2019; 1911: 395-419
- **Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).** *Methods in molecular biology (Clifton, N.J.)*
Bailey, J. R., Urbanowicz, R. A., Ball, J. K., Law, M., Foug, S. K.
2019; 1911: 441–50
- **In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.** *Antiviral research*
Mailly, L., Wrensch, F., Heydmann, L., Fauvelle, C., Brignon, N., Zeisel, M. B., Pessaux, P., Keck, Z., Schuster, C., Fuerst, T. R., Foug, S. K., Baumert, T. F.
2018
- **Editorial: Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine.** *Frontiers in immunology*
Foug, S. K., Baumert, T. F.
2018; 9: 2577

- **Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine** *FRONTIERS IN IMMUNOLOGY*
Foug, S. K. H., Baumert, T. F.
2018; 9
- **Ifitm-Mediated Viral Immune Evasion in Acute and Chronic Hepatitis C Virus Infection**
Wrensch, F., Heydmann, L., Ligat, G., Zeisel, M. B., Pessaux, P., Habersetzer, F., King, B. J., Tarr, A. W., Ball, J. K., Keck, Z., Schuster, C., Foug, S., Baumert, et al
WILEY.2018: 126A
- **Hepatitis C virus (HCV)-Apolipoprotein interactions and immune evasion and Their impact on HCV vaccine Design** *FRONTIERS IN IMMUNOLOGY*
Wrensch, F., Crouchet, E., Ligat, G., Zeisel, M. B., Keck, Z., Foug, S. K. H., Schuster, C., Baumert, T. F.
2018; 9
- **Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.** *Frontiers in immunology*
Wrensch, F., Crouchet, E., Ligat, G., Zeisel, M. B., Keck, Z. Y., Foug, S. K., Schuster, C., Baumert, T. F.
2018; 9: 1436
- **Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine** *FRONTIERS IN IMMUNOLOGY*
Keck, M., Wrensch, F., Pierce, B. G., Baumert, T. F., Foug, S. K. H.
2018; 9: 1194
- **Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine** *SCIENTIFIC REPORTS*
Christiansen, D., Earnest-Silveira, L., Chua, B., Meuleman, P., Boo, I., Grubor-Bauk, B., Jackson, D. C., Keck, Z. Y., Foug, S. H., Drummer, H. E., Gowans, E. J., Torresi, J.
2018; 8: 6483
- **Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus** *FRONTIERS IN MICROBIOLOGY*
Fuerst, T. R., Pierce, B. G., Keck, Z., Foug, S. K. H.
2018; 8
- **Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1** *VIROLOGY*
Mesalam, A., Desombere, I., Farhoudi, A., Van Houtte, F., Verhoye, L., Ball, J., Dubuisson, J., Foug, S. K. H., Patel, A. H., Persson, M. A. A., Leroux-Roels, G., Meuleman, P.
2018; 514: 30–41
- **A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo** *ANTIVIRAL RESEARCH*
Desombere, I., Mesalam, A., Urbanowicz, R. A., Van Houtte, F., Verhoye, L., Keck, Z., Farhoudi, A., Vercauteren, K., Weening, K. E., Baumert, T. F., Patel, A. H., Foug, S. K. H., Ball, et al
2017; 148: 53–64
- **Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.** *mBio*
Vasiliauskaitė, I., Owsianka, A., England, P., Khan, A. G., Cole, S., Bankwitz, D., Foug, S. K., Pietschmann, T., Marcotrigiano, J., Rey, F. A., Patel, A. H., Krey, T.
2017; 8 (3)
- **Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.** *Frontiers in microbiology*
Fuerst, T. R., Pierce, B. G., Keck, Z. Y., Foug, S. K.
2017; 8: 2692
- **Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG** *JOURNAL OF VIROLOGY*
Logan, M., Law, J., Wong, J. A., Hockman, D., Landi, A., Chen, C., Crawford, K., Kundu, J., Baldwin, L., Johnson, J., Dahiya, A., Lachance, G., Marcotrigiano, et al
2017; 91 (1)
- **Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.** *Journal of virology*
Logan, M., Law, J., Wong, J. A., Hockman, D., Landi, A., Chen, C., Crawford, K., Kundu, J., Baldwin, L., Johnson, J., Dahiya, A., LaChance, G., Marcotrigiano, et al

2017; 91 (1)

- **Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies** *EXPERT REVIEW OF VACCINES*
Fauvelle, C., Colpitts, C. C., Keck, Z., Pierce, B. G., Foug, S. K., Baumert, T. F.
2016; 15 (12): 1535-1544
- **Affinity Maturation of a Broadly Neutralizing Human Monoclonal Antibody That Prevents Acute Hepatitis C Virus Infection in Mice** *HEPATOLOGY*
Keck, Z., Wang, Y., Lau, P., Lund, G., Rangarajan, S., Fauvelle, C., Liao, G. C., Holtsberg, F. W., Warfield, K. L., Javad Aman, M., Pierce, B. G., Fuerst, T. R., Bailey, et al
2016; 64 (6): 1922-1933
- **Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Pierce, B. G., Keck, Z., Lau, P., Fauvelle, C., Gowthaman, R., Baumert, T. F., Fuerst, T. R., Mariuzza, R. A., Foug, S. K. H.
2016; 113 (45): E6946–E6954
- **Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.** *Journal of viral hepatitis*
Swann, R. E., Mandalou, P., Robinson, M. W., Ow, M. M., Foug, S. K., McLauchlan, J., Patel, A. H., Cramp, M. E.
2016; 23 (11): 873-880
- **Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.** *Proceedings of the National Academy of Sciences of the United States of America*
Pierce, B. G., Keck, Z., Lau, P., Fauvelle, C., Gowthaman, R., Baumert, T. F., Fuerst, T. R., Mariuzza, R. A., Foug, S. K.
2016
- **Viral evasion and challenges of hepatitis C virus vaccine development.** *Current opinion in virology*
Pierce, B. G., Keck, Z., Foug, S. K.
2016; 20: 55-63
- **Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.** *Hepatology*
Keck, Z., Wang, Y., Lau, P., Lund, G., Rangarajan, S., Fauvelle, C., Liao, G. C., Holtsberg, F. W., Warfield, K. L., Aman, M. J., Pierce, B. G., Fuerst, T. R., Bailey, et al
2016
- **Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.** *Hepatology*
Prentoe, J., Velázquez-Moctezuma, R., Foug, S. K., Law, M., Bukh, J.
2016
- **Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site** *CELL REPORTS*
Howell, K. A., Qiu, X., Brannan, J. M., Bryan, C., Davidson, E., Holtsberg, F. W., Wec, A. Z., Shulenin, S., Biggins, J. E., Douglas, R., Enterlein, S. G., Turner, H. L., Pallesen, et al
2016; 15 (7): 1514-1526
- **Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein** *JOURNAL OF VIROLOGY*
Keck, Z., Enterlein, S. G., Howell, K. A., Hong Vu, H., Shulenin, S., Warfield, K. L., Froude, J. W., Araghi, N., Douglas, R., Biggins, J., Lear-Rooney, C. M., Wirchnianski, A. S., Lau, et al
2016; 90 (1): 279-291
- **Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.** *Journal of virology*
Keck, Z., Girard-Blanc, C., Wang, W., Lau, P., Zuiani, A., Rey, F. A., Krey, T., Diamond, M. S., Foug, S. K.
2016; 90 (6): 3112-3122
- **Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies** *GASTROENTEROLOGY*
Fauvelle, C., Felmlee, D. J., Crouchet, E., Lee, J., Heydmann, L., Lefevre, M., Magri, A., Hiet, M., Fofana, I., Habersetzer, F., Foug, S. K., Milne, R., Patel, et al
2016; 150 (1): 206-?
- **Structural basis for penetration of the glycan shield of hepatitis C virus e2 glycoprotein by a broadly neutralizing human antibody.** *journal of biological chemistry*

- Li, Y., Pierce, B. G., Wang, Q., Keck, Z., Fuerst, T. R., Foug, S. K., Mariuzza, R. A.
2015; 290 (16): 10117-10125
- **An Anti-H5N1 Influenza Virus FcDART Antibody Is a Highly Efficacious Therapeutic Agent and Prophylactic against H5N1 Influenza Virus Infection** *JOURNAL OF VIROLOGY*
Zanin, M., Keck, Z., Rainey, G. J., Lam, C. K., Boon, A. C., Rubrum, A., Darnell, D., Wong, S., Griffin, Y., Xia, J., Webster, R. G., Webby, R., Johnson, et al
2015; 89 (8): 4549-4561
 - **Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein e2 recognized by broadly neutralizing antibodies.** *Journal of virology*
Meola, A., Tarr, A. W., England, P., Meredith, L. W., McClure, C. P., Foug, S. K., McKeating, J. A., Ball, J. K., Rey, F. A., Krey, T.
2015; 89 (4): 2170-2181
 - **Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance** *JOURNAL OF CLINICAL INVESTIGATION*
Bailey, J. R., Wasilewski, L. N., Snider, A. E., El-Diwany, R., Osburn, W. O., Keck, Z., Foug, S. K., Ray, S. C.
2015; 125 (1): 437-447
 - **Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.** *Journal of virology*
Keck, Z., Enterlein, S. G., Howell, K. A., Vu, H., Shulenin, S., Warfield, K. L., Froude, J. W., Araghi, N., Douglas, R., Biggins, J., Lear-Rooney, C. M., Wirchnianski, A. S., Lau, et al
2015; 90 (1): 279-291
 - **Breadth of Neutralization and Synergy of Clinically Relevant Human Monoclonal Antibodies Against HCV Genotypes 1a, 1b, 2a, 2b, 2c, and 3a** *HEPATOLOGY*
Carlsen, T. H., Pedersen, J., Prentoe, J. C., Giang, E., Keck, Z., Mikkelsen, L. S., Law, M., Foug, S. K., Bukh, J.
2014; 60 (5): 1551-1562
 - **Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.** *Hepatology*
Carlsen, T. H., Pedersen, J., Prentoe, J. C., Giang, E., Keck, Z., Mikkelsen, L. S., Law, M., Foug, S. K., Bukh, J.
2014; 60 (5): 1551-1562
 - **Non-random Escape Pathways from a Broadly Neutralizing Human Monoclonal Antibody Map to a Highly Conserved Region on the Hepatitis C Virus E2 Glycoprotein Encompassing Amino Acids 412-423.** *PLoS pathogens*
Keck, Z., Angus, A. G., Wang, W., Lau, P., Wang, Y., Gatherer, D., Patel, A. H., Foug, S. K.
2014; 10 (8)
 - **Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423.** *PLoS pathogens*
Keck, Z., Angus, A. G., Wang, W., Lau, P., Wang, Y., Gatherer, D., Patel, A. H., Foug, S. K.
2014; 10 (8): e1004297
 - **Neutralization Resistance of Hepatitis C Virus Can Be Overcome by Recombinant Human Monoclonal Antibodies** *HEPATOLOGY*
Pedersen, J., Carlsen, T. H., Prentoe, J., Ramirez, S., Jensen, T. B., Forns, X., Alter, H., Foug, S. K., Law, M., Gottwein, J., Weis, N., Bukh, J.
2013; 58 (5): 1587-1597
 - **Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.** *Hepatology (Baltimore, Md.)*
Pedersen, J., Carlsen, T. H., Prentoe, J., Ramirez, S., Jensen, T. B., Forns, X., Alter, H., Foug, S. K., Law, M., Gottwein, J., Weis, N., Bukh, J.
2013
 - **Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape.** *PLoS pathogens*
Krey, T., Meola, A., Keck, Z., Damier-Piolle, L., Foug, S. K., Rey, F. A.
2013; 9 (5)
 - **Contrasting Roles of Mitogen-Activated Protein Kinases in Cellular Entry and Replication of Hepatitis C Virus: MKNK1 Facilitates Cell Entry** *JOURNAL OF VIROLOGY*
Kim, S., Ishida, H., Yamane, D., Yi, M., Swinney, D. C., Foug, S., Lemon, S. M.
2013; 87 (8): 4214-4224
 - **Characterization of Hepatitis C Virus Recombinants with Chimeric E1/E2 Envelope Proteins and Identification of Single Amino Acids in the E2 Stem Region Important for Entry** *JOURNAL OF VIROLOGY*

- Carlsen, T. H., Scheel, T. K., Ramirez, S., Foug, S. K., Bukh, J.
2013; 87 (3): 1385-1399
- **Cooperativity in Virus Neutralization by Human Monoclonal Antibodies to Two Adjacent Regions Located at the Amino Terminus of Hepatitis C Virus E2 Glycoprotein** *JOURNAL OF VIROLOGY*
Keck, Z., Wang, W., Wang, Y., Lau, P., Carlsen, T. H., Prentoe, J., Xia, J., Patel, A. H., Bukh, J., Foug, S. K.
2013; 87 (1): 37-51
 - **Transient Activation of the PI3K-AKT Pathway by Hepatitis C Virus to Enhance Viral Entry** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Liu, Z., Tian, Y., Machida, K., Lai, M. M., Luo, G., Foug, S. K., Ou, J. J.
2012; 287 (50): 41922-41930
 - **Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody** *JOURNAL OF VIROLOGY*
Potter, J. A., Owsianka, A. M., Jeffery, N., Matthews, D. J., Keck, Z., Lau, P., Foug, S. K., Taylor, G. L., Patel, A. H.
2012; 86 (23): 12923-12932
 - **Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies** *GASTROENTEROLOGY*
Fofana, I., Fafi-Kremer, S., Carolla, P., Fauvelle, C., Zahid, M. N., Turek, M., Heydmann, L., Cury, K., Hayer, J., Combet, C., Cosset, F., Pietschmann, T., Hiet, et al
2012; 143 (1): 223-U429
 - **Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate** *PLOS PATHOGENS*
Keck, Z., Xia, J., Wang, Y., Wang, W., Krey, T., Prentoe, J., Carlsen, T., Li, A. Y., Patel, A. H., Lemon, S. M., Bukh, J., Rey, F. A., Foug, et al
2012; 8 (4)
 - **IMMUNE RESPONSES AGAINST FOUNDER HEPATITIS C VIRUSES IN ACUTE ASYMPTOMATIC SUBJECTS** *47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL)*
Luciani, F., Bull, R. A., Cameron, B., Gaudieri, S., Nguyen, N., Yuen, D., White, P. A., Purcell, D. F., Foug, S., Lloyd, A. R.
ELSEVIER SCIENCE BV.2012: S312-S312
 - **Affinity Maturation to Improve Human Monoclonal Antibody Neutralization Potency and Breadth against Hepatitis C Virus** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Wang, Y., Keck, Z., Saha, A., Xia, J., Conrad, F., Lou, J., Eckart, M., Marks, J. D., Foug, S. K.
2011; 286 (51): 44218-44233
 - **Neutralizing Antibody Response to Hepatitis C Virus** *VIRUSES-BASEL*
Wang, Y., Keck, Z., Foug, S. K.
2011; 3 (11): 2127-2145
 - **Mapping a Region of Hepatitis C Virus E2 That Is Responsible for Escape from Neutralizing Antibodies and a Core CD81-Binding Region That Does Not Tolerate Neutralization Escape Mutations** *JOURNAL OF VIROLOGY*
Keck, Z., Saha, A., Xia, J., Wang, Y., Lau, P., Krey, T., Rey, F. A., Foug, S. K.
2011; 85 (20): 10451-10463
 - **Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships** *JOURNAL OF GENERAL VIROLOGY*
Rychlowska, M., Owsianka, A. M., Foug, S. K., Dubuisson, J., Bienkowska-Szewczyk, K., Patel, A. H.
2011; 92: 2249-2261
 - **The Hepatitis C Virus E1 Glycoprotein Undergoes Productive Folding but Accelerated Degradation When Expressed as an Individual Subunit in CHO Cells** *PLOS ONE*
Botti, V., Bianchi, A., Foug, S. K., Merola, M.
2011; 6 (8)
 - **CELL ENTRY FACTOR USAGE AND VIRAL EVASION IN HEPATITIS C VIRUS INFECTION IN VIVO**
Carolla, P., Fofana, I., Fafi-Kremer, S., Zahid, M. N., Cury, K., Turek, M., Bastien-Valle, M., Cosset, F., Pietschmann, T., Hayer, J., Combet, C., Habersetzer, F., Dofoeel, et al
ELSEVIER SCIENCE BV.2011: S315

- **The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae** *JOURNAL OF GENERAL VIROLOGY*
Stapleton, J. T., Fong, S., Muerhoff, A. S., Bukh, J., Simmonds, P.
2011; 92: 233-246
- **Hepatitis C virus e2 protein ectodomain is essential for assembly of infectious virions.** *International journal of hepatology*
Bianchi, A., Crotta, S., Brazzoli, M., Fong, S. K., Merola, M.
2011; 2011: 968161-?
- **IDENTIFICATION OF RESIDUES IN HCV E2 GLYCOPROTEIN THAT AFFECT NEUTRALIZATION BY HUMAN ANTIBODIES IN SERA OF INFECTED PATIENTS-IMPLICATIONS FOR ANTI-HCV VACCINE DEVELOPMENT** *61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases*
Gal-Tanamy, M., Zemel, R., Yi, M., Fong, S., Lemon, S. M., Tur-Kaspa, R.
WILEY-BLACKWELL.2010: 820A-820A
- **MOLECULAR MECHANISMS OF VIRAL EVASION IN ACUTE HEPATITIS C VIRUS LIVER GRAFT INFECTION**
Carolla, P., Fofana, I., Fafi-Kremer, S., Cury, K., Zahid, M., Turek, M., Bastien-Valle, M., Grunert, F., Cosset, F., Pietschmann, T., Habersetzer, F. T., Wolf, P., Keck, et al
WILEY-BLACKWELL.2010: 739A
- **Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes** *JOURNAL OF VIROLOGY*
Bankwitz, D., Steinmann, E., Bitzegeio, J., Ciesek, S., Friesland, M., Herrmann, E., Zeisel, M. B., Baumert, T. F., Keck, Z., Fong, S. K., Pecheur, E., Pietschmann, T.
2010; 84 (11): 5751-5763
- **Mutations within a Conserved Region of the Hepatitis C Virus E2 Glycoprotein That Influence Virus-Receptor Interactions and Sensitivity to Neutralizing Antibodies** *JOURNAL OF VIROLOGY*
Dhillon, S., Witteveldt, J., Gatherer, D., Owsianka, A. M., Zeisel, M. B., Zahid, M. N., Rychlowska, M., Fong, S. K., Baumert, T. F., Angus, A. G., Patel, A. H.
2010; 84 (11): 5494-5507
- **TWO MUTATIONS IN HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN DOMAIN E2(424-482) MEDIATE ENHANCED INFECTIVITY OF A VIRAL VARIANT SELECTED DURING RE-INFECTED OF THE LIVER GRAFT**
Carolla, P., Fofana, I., Fafi-Kremer, S., Soulier, E., Bastien-Valle, M., Cosset, F., Fong, S., Dofoel, M., Wolf, P., Stoll-Keller, F., Baumert, T. F.
JOHN WILEY & SONS INC.2009: 544A
- **Antigen-specific Proteolysis by Hybrid Antibodies Containing Promiscuous Proteolytic Light Chains Paired with an Antigen-binding Heavy Chain** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Sapparapu, G., Planque, S. A., Nishiyama, Y., Fong, S. K., Paul, S.
2009; 284 (36): 24622-24633
- **CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells** *JOURNAL OF GENERAL VIROLOGY*
Witteveldt, J., Evans, M. J., Bitzegeio, J., Koutsoudakis, G., Owsianka, A. M., Angus, A. G., Keck, Z., Fong, S. K., Pietschmann, T., Rice, C. M., Patel, A. H.
2009; 90: 48-58
- **Hepatitis C VACCINES FOR BIODEFENSE AND EMERGING AND NEGLECTED DISEASES**
Gal-Tanamy, M., Walker, C., Fong, S., Lemon, S. M.
edited by Barrett, A. D., Stanberry, L. R.
2009: 413-40
- **In vitro selection of a neutralization-resistant hepatitis C virus escape mutant** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Gal-Tanamy, M., Keck, Z., Yi, M., McKeating, J. A., Patel, A. H., Fong, S. K., Lemon, S. M.
2008; 105 (49): 19450-19455
- **Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein** *JOURNAL OF VIROLOGY*
Machida, K., Kondo, Y., Huang, J. Y., Chen, Y., Cheng, K. T., Keck, Z., Fong, S., Dubuisson, J., Sung, V. M., Lai, M. M.
2008; 82 (13): 6711-6720

- **A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope** *JOURNAL OF VIROLOGY*
Keck, Z., Olson, O., Gal-Tanamy, M., Xia, J., Patel, A. H., Dreux, M., Cosset, F., Lemon, S. M., Foug, S. K.
2008; 82 (12): 6067-6072
- **Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies** *JOURNAL OF VIROLOGY*
Keck, Z., Li, T., Xia, J., Gal-Tanamy, M., Olson, O., Li, S. H., Patel, A. H., Ball, J. K., Lemon, S. M., Foug, S. K.
2008; 82 (12): 6061-6066
- **Antibody-dependent enhancement of hepatitis C virus infection** *JOURNAL OF VIROLOGY*
Meyer, K., Ait-Goughoulte, M., Keck, Z., Foug, S., Ray, R.
2008; 82 (5): 2140-2149
- **Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein** *JOURNAL OF GENERAL VIROLOGY*
Owsianka, A. M., Tarr, A. W., Keck, Z., Li, T., Witteveldt, J., Adair, R., Foug, S. K., Ball, J. K., Patel, A. H.
2008; 89: 653-659
- **Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein** *BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS*
Iacob, R. E., Keck, Z., Olson, O., Foug, S. K., Tomer, K. B.
2008; 1784 (3): 530-542
- **Therapeutic control of hepatitis C virus: The role of neutralizing monoclonal antibodies** *HUMAN ANTIBODY THERAPEUTICS FOR VIRAL DISEASE*
Keck, Z. Y., Machida, K., Lai, M. M., Ball, J. K., Patel, A. H., Foug, S. K.
2008; 317: 1-38
- **The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein** *JOURNAL OF VIROLOGY*
Helle, F., Goffard, A., Morel, V., Duverlie, G., McKeating, J., Keck, Z., Foug, S., Penin, F., Dubuisson, J., Voisset, C.
2007; 81 (15): 8101-8111
- **Directing the natural catalytic activity of antibodies to hepatitis C virus E2 protein**
Sapparapu, G., Planque, S. A., Wang, R., Nishiyama, Y., Keck, Z., Foug, S., Paul, S.
AMER ASSOC IMMUNOLOGISTS.2007
- **Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions** *JOURNAL OF VIROLOGY*
Keck, Z., Xia, J., Cai, Z., Li, T., Owsianka, A. M., Patel, A. H., Luo, G., Foug, S. K.
2007; 81 (2): 1043-1047
- **High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Dreux, M., Pietschmann, T., Granier, C., Voisset, C., Ricard-Blum, S., Mangeot, P., Keck, Z., Foug, S., Vu-Dac, N., Dubuisson, J., Bartenschlager, R., Lavillette, D., Cosset, et al
2006; 281 (27): 18285-18295
- **HDL inhibits HCV neutralisation by CD81-NOB antibodies by stimulating cell entry through activation of the scavenger receptor BI**
Dreux, M., Pietschmann, T., Granier, C., Voisset, C., Ricard-Blum, S., Mangeot, P., Keck, Z., Foug, S., Vu-Dac, N., Dubuisson, J., Bartenschlager, R., Lavillette, D., Cosset, et al
ELSEVIER SCIENCE BV.2006: S52-S53
- **HDL inhibits neutralisation by HCV antibodies via a ternary interaction with the scavenger receptor BI**
Dreux, M., Pietschmann, T., Granier, C., Voisset, C., Ricard-Blum, S., Mangeot, P. E., Keck, Z., Foug, S., Vu-Dac, N., Dubuisson, J., Bartenschlager, R., Lavillette, D., Cosset, et al
ELSEVIER SCIENCE BV.2006: S42
- **Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): A potential treatment to prevent HCV reinfection in liver transplant patients** *JOURNAL OF VIROLOGY*
Eren, R., Landstein, D., Terkieltaub, D., Nussbaum, O., Zauberman, A., Ben-Porath, J., Gopher, J., Buchnick, R., Kovjazin, R., Rosenthal-Galili, Z., Aviel, S., Ilan, E., Shoshany, et al

2006; 80 (6): 2654-2664

- **Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6** *JOURNAL OF VIROLOGY*
Machida, K., Cheng, K. T., Sung, V. M., Levine, A. M., Foug, S., Lai, M. M.
2006; 80 (2): 866-874
- **Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2** *JOURNAL OF VIROLOGY*
Keck, Z. Y., Li, T. K., Xia, J. M., Bartosch, B., Cosset, F. L., Dubuisson, J., Foug, S. K.
2005; 79 (21): 13199-13208
- **Preclinical evaluation of two neutralizing human monoclonal antibodies against HCV: A potential treatment to prevent HCV re-infection in liver transplant patients**
Eren, R., Landstein, D., Kovjazin, R., Rosenthal-Galili, Z., Waisman, T., Aviel, S., Terkieltaub, D., Gopher, J., Ilan, E., Zauberman, A., Keck, Z. Y., Foug, S., Dagan, et al
ELSEVIER SCIENCE BV.2005: 204
- **Preclinical evaluation of two neutralizing human monoclonal antibodies against HCV: A potential treatment to prevent HCV re-infection in liver transplant patients**
Ilan, E., Eren, R., Landstein, D., Kovjazin, R., Galili, Z., Waisman, T., Aviel, S., Terkieltaub, D., Gopher, J., Zauberman, A., Keck, Z. Y., Foug, S., Dagan, et al
ELSEVIER SCIENCE BV.2005: A58
- **Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells** *VIROLOGY*
Brazzoli, M., HELENIUS, A., Foug, S. K., Houghton, M., Abrignani, S., Merola, M.
2005; 332 (1): 438-453
- **Preclinical evaluation of two neutralizing human monoclonal antibodies against HCV: A potential treatment to prevent HCV reinfection in liver transplant patients**
Eren, R., Landstein, D., Kovjazin, R., Aviel, S., Terkieltaub, D., Buchnick, R., Gopher, J., Ilan, E., Zauberman, A., Keck, Z. Y., Foug, S., Galun, E., Dagan, et al
JOHN WILEY & SONS INC.2004: 281A
- **Antibody light chain-catalyzed hydrolysis of a hepatitis C virus peptide** *BIOORGANIC & MEDICINAL CHEMISTRY LETTERS*
Taguchi, H., Keck, Z. Y., Foug, S. K., Paul, S., Nishiyama, Y.
2004; 14 (17): 4529-4532
- **Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions** *JOURNAL OF VIROLOGY*
Keck, Z. Y., Op de Beeck, A., Hadlock, K. G., Xia, J. M., Li, T. K., Dubuisson, J., Foug, S. K.
2004; 78 (17): 9224-9232
- **Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity** *JOURNAL OF VIROLOGY*
Keck, Z. Y., Sung, V. M., Perkins, S., Rowe, J., Paul, S., Liang, T. J., Lai, M. M., Foug, S. K.
2004; 78 (13): 7257-7263
- **Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein** *JOURNAL OF IMMUNOLOGY*
Heo, T. H., Chang, J. H., Lee, J. W., Foug, S. K., Dubuisson, J., Kang, C. Y.
2004; 173 (1): 446-455
- **Characterization of functional hepatitis C virus envelope glycoproteins** *JOURNAL OF VIROLOGY*
De Beeck, A. O., Voisset, C., Bartosch, B., Ciczora, Y., Cocquerel, L., Keck, Z., Foug, S., Cosset, F. L., Dubuisson, J.
2004; 78 (6): 2994-3002
- **DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Lozach, P. Y., Lortat-Jacob, H., de Lavalette, A. D., Staropoli, I., Foug, S., Amara, A., Houles, C., Fieschi, F., Schwartz, O., Virelizier, J. L., Arenzana-Seisdedos, F., Altmeyer, R.
2003; 278 (22): 20358-20366
- **Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody** *JOURNAL OF VIROLOGY*
Cocquerel, L., Quinn, E. R., Flint, M., Hadlock, K. G., Foug, S. K., Levy, S.

2003; 77 (2): 1604-1609

- **Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding** *VIROLOGY*
Triyatni, M., Vergalla, J., Davis, A. R., Hadlock, K. G., Foug, S. K., Liang, T. J.
2002; 298 (1): 124-132
- **Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras** *AIDS RESEARCH AND HUMAN RETROVIRUSES*
Hadlock, K. G., Yang, Q., Rowe, J., Foug, S. K.
2002; 18 (1): 57-70
- **The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis** *BLOOD*
Quinn, E. R., Chan, C. H., Hadlock, K. G., Foug, S. K., Flint, M., Levy, S.
2001; 98 (13): 3745-3749
- **Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2)** *JOURNAL OF MEDICAL VIROLOGY*
Hadlock, K. G., Gish, R., Rowe, J., Rajyaguru, S. S., Newsom, M., Warford, A., Foug, S. K.
2001; 65 (1): 23-29
- **Evaluation of human monoclonal antibodies to HCV in the HCV-Trimer model: A mouse model for HCV infection**
Nussbaum, O., Ilan, E., Eren, R., Zauberman, A., Porat, Y., Neville, L., Arazi, Y., Livneh, G., Shavit, S., Hadlock, K., Foug, S., Dagan, S.
ELSEVIER SCIENCE BV.2001: 26
- **V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen** *BLOOD*
Chan, C. H., Hadlock, K. G., Foug, S. K., Levy, S.
2001; 97 (4): 1023-1026
- **Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes** *JOURNAL OF VIROLOGY*
Hadlock, K. G., Lanford, R. E., Perkins, S., Rowe, J., Yang, Q., Levy, S., Pileri, P., Abrignani, S., Foug, S. K.
2000; 74 (22): 10407-10416
- **Preferential expression of the VH1-69 gene in an anti-hepatitis C virus (HCV) immune response in an HCV-infected individual**
Chan, C. H., Hadlock, K. G., Perkins, S. L., Foug, S. K., Levy, S.
FEDERATION AMER SOC EXP BIOL.2000: A1122-A1122
- **The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes** *JOURNAL OF VIROLOGY*
Hadlock, K. G., Rowe, J., Foug, S. K.
1999; 73 (2): 1205-1212
- **Human monoclonal antibodies to conserved conformational epitopes within hepatitis C virus E2 protein.**
Hadlock, K. G., Yang, Q., Rowe, J., Perkins, S., Lanford, R., Foug, S. K.
WILEY-BLACKWELL.1998: 275A-275A
- **Large granular lymphocyte leukaemia occurring after renal transplantation** *BRITISH JOURNAL OF HAEMATOLOGY*
Gentile, T. C., Hadlock, K. G., Uner, A. H., Delal, B., Squiers, E., CROWLEY, S., Woodman, R. C., Foug, S. K., Poiesz, B. J., Loughran, T. P.
1998; 101 (3): 507-512
- **Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia** *BRITISH JOURNAL OF HAEMATOLOGY*
Loughran, T. P., Hadlock, K. G., Perzova, R., Gentile, T. C., Yang, Q., Foug, S. K., Poiesz, B. J.
1998; 101 (2): 318-324
- **GBV-C/HGV: A new virus within the Flaviviridae and its clinical implications** *TRANSFUSION MEDICINE REVIEWS*
Hadlock, K. G., Foug, S. K.
1998; 12 (2): 94-108

- **Experimental infection of chimpanzees with hepatitis G virus and genetic analysis of the virus** *16th Annual Meeting of the American-Society-for-Virology*
Bukh, J., Kim, J. P., Govindarajan, S., Apgar, C. L., Foug, S. K., Wages, J., Yun, A. J., Shapiro, M., Emerson, S. U., Purcell, R. H.
OXFORD UNIV PRESS INC.1998: 855-62
- **Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3(-) (natural killer) lymphoproliferative disease of granular lymphocytes** *BLOOD*
Loughran, T. P., Hadlock, K. G., Yang, Q., Perzova, R., Zambello, R., Semenzato, G., Foug, S. K., Poesz, B. J.
1997; 90 (5): 1977-1981
- **Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46** *JOURNAL OF VIROLOGY*
Hadlock, K. G., Rowe, J., Perkins, S., Bradshaw, P., Song, G. Y., Cheng, C., Yang, J., Gascon, R., HALMOS, J., REHMAN, S. M., McGrath, M. S., Foug, S. K.
1997; 71 (8): 5828-5840
- **A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: Expression of gp46 by the vaccinia virus T7 polymerase system** *JOURNAL OF VIROLOGY*
Arp, J., LEVATTE, M., Rowe, J., Perkins, S., King, E., LEYSTRALANTZ, C., Foug, S. K., Dekaban, G. K.
1996; 70 (11): 7349-7359
- **Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent** *SCIENCE*
Linnen, J., Wages, J., ZHANGKECK, Z. Y., Fry, K. E., KRAWCZYNSKI, K. Z., Alter, H., Koonin, E., Gallagher, M., Alter, M., Hadziyannis, S., Karayiannis, P., Fung, K., Nakatsuji, et al
1996; 271 (5248): 505-508
- **ENHANCED SPECIFICITY OF TRUNCATED TRANSMEMBRANE PROTEIN FOR SEROLOGIC CONFIRMATION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-1 (HTLV-1) AND HTLV-2 INFECTIONS BY WESTERN-BLOT (IMMUNOBLOT) ASSAY CONTAINING RECOMBINANT ENVELOPE GLYCOPROTEINS** *JOURNAL OF CLINICAL MICROBIOLOGY*
Varma, M., Rudolph, D. L., KNUCHEL, M., Switzer, W. M., Hadlock, K. G., Velligan, M., Chan, L., Foug, S. K., Lal, R. B.
1995; 33 (12): 3239-3244
- **DELINEATION OF IMMUNOGENIC REGIONS WITHIN HTLV-I AND HTLV-II P24**
Hadlock, K. G., Cheng, C., Yang, Q., Perkins, S., Rowe, J., Foug, S. K.
LIPPINCOTT WILLIAMS & WILKINS.1995: 136-36
- **BIOCHEMICAL AND CONFORMATIONAL INTEGRITY OF RECOMBINANT HTLV-I GP46 ENVELOPE PROTEIN EXPRESSED IN A VACCINIA/T7 POLYMERASE SYSTEM**
ARP, J., LEVATTE, M., FOUNG, S., ROWE, J., DEKABAN, G. A.
LIPPINCOTT-RAVEN PUBL.1995: 41
- **DELINEATION OF AN IMMUNODOMINANT AND HUMAN T-CELL LYMPHOTROPIC VIRUS (HTLV)-SPECIFIC EPITOPE WITHIN THE HTLV-I TRANSMEMBRANE GLYCOPROTEIN** *BLOOD*
Hadlock, K. G., Goh, C. J., BRADSHAW, P. A., Perkins, S., Lo, J., Kaplan, J. E., Khabbaz, R., Foug, S. K.
1995; 86 (4): 1392-1399
- **Stabilizing antibody secretion of human Epstein Barr virus-activated B-lymphocytes with hybridoma formation by electrofusion.** *Methods in molecular biology (Clifton, N.J.)*
Perkins, S., FOUNG, S. K.
1995; 48: 295-307
- **LOCALIZATION OF ANTIGENIC SITES ON HUMAN CYTOMEGALOVIRUS VIRION STRUCTURAL PROTEINS ENCODED BY UL48 AND UL56** *VIROLOGY*
BRADSHAW, P. A., DURANGUARINO, M. R., Perkins, S., ROWE, J. I., Fernandez, J., Fry, K. E., Reyes, G. R., Young, L., Foug, S. K.
1994; 205 (1): 321-328
- **DELINEATION OF AN IMMUNODOMINANT AND HIGHLY HTLV SPECIFIC EPITOPE WITHIN HTLV-I GP21**
Hadlock, K. G., Goh, C. J., BRADSHAW, P. A., Perkins, S., Lo, J., Khabbaz, R., Kaplan, J., Foug, S. K.
MARY ANN LIEBERT INC.1994: 499-99
- **MOLECULAR BIOLOGICAL EVIDENCE FOR HTLV-1 PROVIRAL INTEGRATION IN SOME CASES OF MYCOSIS-FUNGOIDES SEZARY-SYNDROME (MF/SS)**

WOOD, G. S., SALVEKAR, A., CROOKS, C. F., BONI, R., HENGHOLD, W., SCHWANDT, A., FOUNG, S., WARNKE, R. A., BURG, G.
BLACKWELL SCIENCE INC.1994: 543

- **IMPROVED DETECTION OF HTLV USING RECOMBINANT PROTEIN-DERIVED FROM GP21 REGION**
Varma, M., Chan, L., Walsh, A., Song, G. Y., TOSTADO, M., Hadlock, K., Foug, S., Lal, R.
MARY ANN LIEBERT INC.1994: 495-95
- **NEUTRALIZING HTLV-I HUMAN MONOCLONAL-ANTIBODIES (HMABS) TO CONFORMATIONAL EPITOPES**
Rowe, J., Perkins, S., Bradshaw, P., Song, G. Y., Foug, S.
MARY ANN LIEBERT INC.1994: 509-
- **IMMUNOGLOBULIN PROPHYLAXIS AGAINST HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-II IN RABBITS** *JOURNAL OF INFECTIOUS DISEASES*
Morishita, N., Ishii, K., Tanaka, Y., Sawada, T., Hoshino, H., Foug, S. K., Miyoshi, I.
1994; 169 (3): 620-623
- **AMPLIFICATION AND DETECTION OF A SINGLE-MOLECULE OF HUMAN-IMMUNODEFICIENCY-VIRUS RNA** *VIRUS GENES*
Nakamura, S., Katamine, S., Yamamoto, T., Foug, S. K., Kurata, T., HIRABAYASHI, Y., Shimada, K., Hino, S., Miyamoto, T.
1993; 7 (4): 325-338
- **HUMAN T-LYMPHOTROPIC VIRUS TYPE-III IN LAKE LINDU VALLEY, CENTRAL SULAWESI, INDONESIA** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY*
Lal, R. B., LIPKA, J. J., Foug, S. K., Hadlock, K. G., Reyes, G. R., Carney, W. P.
1993; 6 (9): 1067-1068
- **DETERMINATION OF IMMUNODOMINANT EPITOPE WITHIN HTLV-I GP21**
BRADSHAW, P. A., Lo, J., Perkins, S., Foug, S. K., Hadlock, K. G., Goh, C. J., Chan, L., Ruda, M.
WILEY-BLACKWELL.1993: S39-S39
- **ASSOCIATION OF (TROPICAL) ATAXIC NEUROPATHY WITH HTLV-II** *VIRUS RESEARCH*
Sheremata, W. A., Harrington, W. J., BRADSHAW, P. A., Foug, S. K., Raffanti, S. P., Berger, J. R., Snodgrass, S., Resnick, L., Poiesz, B. J.
1993; 29 (1): 71-77
- **ISOTYPIC AND IGG SUBCLASS RESTRICTION OF THE HUMORAL IMMUNE-RESPONSES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I** *CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY*
Lal, R. B., Buckner, C., Khabbaz, R. F., Kaplan, J. E., Reyes, G., Hadlock, K., Lipka, J., Foug, S. K., Chan, L., Coligan, J. E.
1993; 67 (1): 40-49
- **SPASTIC ATAXIA ASSOCIATED WITH HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-II INFECTION** *ANNALS OF NEUROLOGY*
Harrington, W. J., Sheremata, W., Hjelle, B., Dube, D. K., Bradshaw, P., Foug, S. K., Snodgrass, S., TOEDTER, G., Cabral, L., Poiesz, B.
1993; 33 (4): 411-414
- **EVALUATION OF AN IMMUNOBLOT ASSAY FOR SEROLOGICAL CONFIRMATION AND DIFFERENTIATION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I AND TYPE-II** *JOURNAL OF CLINICAL MICROBIOLOGY*
Roberts, B. D., Foug, S. K., LIPKA, J. J., Kaplan, J. E., Hadlock, K. G., Reyes, G. R., Chan, L., Heneine, W., Khabbaz, R. F.
1993; 31 (2): 260-264
- **NEUTRALIZING ANTIBODY TO VESICULAR STOMATITIS-VIRUS (HTLV-I) PSEUDOTYPE IN INFANTS BORN TO SEROPOSITIVE MOTHERS** *JAPANESE JOURNAL OF CANCER RESEARCH*
Iwahara, Y., Sawada, T., Taguchi, H., Hoshino, H., Umemoto, M., Take, H., Foug, S., Miyoshi, I.
1993; 84 (2): 114-116
- **IMMUNE RESPONSIVENESS TO THE IMMUNODOMINANT RECOMBINANT ENVELOPE EPITOPES OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-1 AND TYPE-2 IN DIVERSE GEOGRAPHIC POPULATIONS** *JOURNAL OF INFECTIOUS DISEASES*
Buckner, C., ROBERTS, C. R., Foug, S. K., Lipka, J., Reyes, G. R., Hadlock, K., Chan, L., GONGORABIACHI, A., Hjelle, B., Lal, R. B.
1992; 166 (5): 1160-1163
- **EPITOPE MAPPING OF THE HTLV-I SPECIFIC AND IMMUNODOMINANT RECOMBINANT PROTEIN MTA-1**
Mishra, A., LIPKA, J. J., Foug, S. K., Guan, M., Reyes, G. R., Hadlock, K. G.
AMER ASSOC BLOOD BANKS.1992: S34-S34

- **DIAGNOSIS OF HTLV-I AND HTLV-II INFECTIONS AMONG UNITED-STATES BLOOD-DONORS**
SVOBODA, S., LIPKA, J. J., FOUNG, S. K., CHAN, L., BUSCH, M., FANG, C. T.
AMER ASSOC BLOOD BANKS.1992: S34
- **EVALUATION OF AN IMMUNOBLOT ASSAY FOR SEROLOGICAL CONFIRMATION AND DIFFERENTIATION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I AND TYPE-II**
ROBERTS, B. D., FOUNG, S. K., LIPKA, J. J., KAPLAN, J. E., HADLOCK, K. G., REYES, G. R., CHAN, L., HENEINE, W., KHABBAZ, R. F.
AMER ASSOC BLOOD BANKS.1992: S58
- **CLONING AND ANALYSIS OF A RECOMBINANT ANTIGEN CONTAINING AN EPITOPE SPECIFIC FOR HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-II** *BLOOD*
Hadlock, K. G., LIPKA, J. J., Chow, T. P., Fong, S. K., Reyes, G. R.
1992; 79 (10): 2789-2796
- **SEROLOGIC CONFIRMATION OF SIMIAN T-LYMPHOTROPIC VIRUS TYPE-I INFECTION BY USING IMMUNOASSAYS DEVELOPED FOR HUMAN T-LYMPHOTROPIC VIRUS-ANTIBODY DETECTION** *JOURNAL OF CLINICAL MICROBIOLOGY*
Rudolph, D. L., Yee, J., Mone, J., Fong, S. K., LIPKA, J. J., Reyes, G. R., Hadlock, K., Chan, L., Villinger, F., Lairmore, M. D., Sinha, S., Lal, R. B.
1992; 30 (4): 858-861
- **SEGREGATION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I AND TYPE-II INFECTIONS BY ANTIBODY REACTIVITY TO UNIQUE VIRAL EPITOPES** *JOURNAL OF INFECTIOUS DISEASES*
LIPKA, J. J., Miyoshi, I., Hadlock, K. G., Reyes, G. R., Chow, T. P., Blattner, W. A., Shaw, G. M., Hanson, C. V., Gallo, D., Chan, L., Fong, S. K.
1992; 165 (2): 268-272
- **PRODUCTION OF HTLV-I HUMAN MONOCLONAL-ANTIBODIES**
REHMAN, S. M., Perkins, S., Rowe, J., Fong, S. K.
MOSBY-ELSEVIER.1992: 264-64
- **ANTIBODIES TO HEPATITIS-C VIRUS IN LOW-RISK BLOOD-DONORS - IMPLICATIONS FOR COUNSELING POSITIVE DONORS** *GASTROENTEROLOGY*
Hsu, H. H., Gonzalez, M., Fong, S. K., Feinstone, S. M., Greenberg, H. B.
1991; 101 (6): 1724-1727
- **MODIFIED WESTERN-BLOT ASSAY FOR CONFIRMATION AND DIFFERENTIATION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I AND TYPE-II** *JOURNAL OF INFECTIOUS DISEASES*
LIPKA, J. J., Santiago, P., Chan, L., Reyes, G. R., Samuel, K. P., Blattner, W. A., Shaw, G. M., Hanson, C. V., Sninsky, J. J., Fong, S. K.
1991; 164 (2): 400-403
- **Parameters to enhance human hybridoma formation with hypoosmolar electrofusion.** *Human antibodies and hybridomas*
Perkins, S., Zimmermann, U., FOUNG, S. K.
1991; 2 (3): 155-159
- **HTLV-I-ASSOCIATED MYELOPATHY IN A CALIFORNIAN - DIAGNOSIS BY REACTIVITY TO A VIRAL RECOMBINANT ANTIGEN** *NEUROLOGY*
Honig, L. S., LIPKA, J. J., Young, K. Y., Weiss, J. H., Fong, S. K.
1991; 41 (3): 448-450
- **SIGNIFICANCE OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-I INDETERMINANT SEROLOGICAL FINDINGS AMONG HEALTHY-INDIVIDUALS** *VOX SANGUINIS*
LIPKA, J. J., Young, K. K., Kwok, S. Y., Reyes, G. R., Sninsky, J. J., Fong, S. K.
1991; 61 (3): 171-176
- **DEVELOPMENT OF MICROFUSION TECHNIQUES TO GENERATE HUMAN HYBRIDOMAS** *JOURNAL OF IMMUNOLOGICAL METHODS*
Fong, S., Perkins, S., Kafadar, K., Gessner, P., Zimmermann, U.
1990; 134 (1): 35-42
- **EFFICIENT HYBRIDIZATION OF MOUSE-HUMAN CELL-LINES BY MEANS OF HYPOOSMOLAR ELECTROFUSION** *JOURNAL OF IMMUNOLOGICAL METHODS*
Zimmermann, U., Gessner, P., Schnettler, R., Perkins, S., Fong, S. K.
1990; 134 (1): 43-50

- **DETERMINATION OF A UNIQUE AND IMMUNODOMINANT EPITOPE OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I** *JOURNAL OF INFECTIOUS DISEASES*
LIPKA, J. J., Bui, K., Reyes, G. R., Moeckli, R., Wiktor, S. Z., Blattner, W. A., Murphy, E. L., Shaw, G. M., Hanson, C. V., Sninsky, J. J., Foug, S. K.
1990; 162 (2): 353-357
- **LOW INCIDENCE OF HTLV INFECTIONS IN RANDOM BLOOD-DONORS WITH INDETERMINATE WESTERN-BLOT PATTERNS** *TRANSFUSION*
Kwok, S., LIPKA, J. J., McKinney, N., KELLOGG, D. E., Poiesz, B., Foug, S. K., Sninsky, J. J.
1990; 30 (6): 491-494
- **GENERATION OF A HUMAN HYBRIDOMA PRODUCING A PURE ANTI-HLA-A2 MONOCLONAL-ANTIBODY** *HUMAN IMMUNOLOGY*
WALLACE, E. F., Foug, S. K., Bradbury, K., PASK, S. L., GRUMET, F. C.
1990; 28 (1): 65-69
- **ENHANCING THE SENSITIVITY OF HTLV-I IMMUNOASSAYS** *CONF ON HUMAN RETROVIROLOGY : HTLV (HUMAN T-CELL LYMPHOTROPIC VIRUS)*
LIPKA, J. J., Parker, J. L., Foug, S. K.
RAVEN PRESS.1990: 409-417
- **HUMAN MONOCLONAL-ANTIBODIES TO HUMAN CYTOMEGALO-VIRUS** *JOURNAL OF INFECTIOUS DISEASES*
Foug, S. K., Perkins, S., Bradshaw, P., Rowe, J., RABIN, L. B., Reyes, G. R., Lennette, E. T.
1989; 159 (3): 436-443
- **ELECTRIC FIELD-INDUCED CELL-FUSION AND HUMAN MONOCLONAL-ANTIBODIES** *JOURNAL OF IMMUNOLOGICAL METHODS*
Foug, S. K., Perkins, S.
1989; 116 (1): 117-122
- **INITIAL IDENTIFICATION AND MAPPING OF DISTINCT RH0 (D) EPITOPES** *REVUE FRANCAISE DE TRANSFUSION ET IMMUNO-HEMATOLOGIE*
Rodriguez, L., WINN, L., Foug, S. K.
1988; 31 (2): 223-231
- **THE EFFICACY OF PLA1-NEGATIVE PLATELET TRANSFUSION THERAPY IN POSTTRANSFUSION PURPURA** *WESTERN JOURNAL OF MEDICINE*
Lippman, S. M., LIZAK, G. E., Foug, S. K., GRUMET, F. C.
1988; 148 (1): 86-88
- **CYTOMEGALO-VIRUS ANTIGENS IDENTIFIED BY HUMAN MONOCLONAL-ANTIBODIES**
BRADSHAW, P. A., Perkins, S., Lennette, E., HAYES, C. F., Foug, S. K.
ELSEVIER SCIENCE BV.1988: 158-58
- **HUMAN MONOCLONAL-ANTIBODIES TO RH0(D)** *VOX SANGUINIS*
Foug, S. K., Blunt, J. A., Wu, P. S., AHEARN, P., WINN, L. C., Engleman, E. G., GRUMET, F. C.
1987; 53 (1): 44-47
- **HUMAN MONOCLONAL ANTI-T-CELL ANTIBODY FROM A PATIENT WITH JUVENILE RHEUMATOID-ARTHRITIS** *JOURNAL OF IMMUNOLOGY*
ALPERT, S. D., Turek, P. J., Foug, S. K., Engleman, E. G.
1987; 138 (1): 104-108
- **EARLY IMMUNE-RESPONSE IN HEALTHY AND IMMUNOCOMPROMISED SUBJECTS WITH PRIMARY VARICELLA-ZOSTER VIRUS-INFECTION** *JOURNAL OF INFECTIOUS DISEASES*
Arvin, A. M., Koropchak, C. M., Williams, B. R., GRUMET, F. C., Foug, S. K.
1986; 154 (3): 422-429
- **A MONOCLONAL-ANTIBODY AGAINST HLA-A11 AND A24** *HUMAN IMMUNOLOGY*
Foug, S. K., Taidi, B., Ness, D., GRUMET, F. C.
1986; 15 (3): 316-319
- **A HUMAN MONOCLONAL-ANTIBODY TO RHG** *VOX SANGUINIS*
Foug, S. K., Blunt, J., Perkins, S., WINN, L., GRUMET, F. C.

1986; 50 (3): 160-163

- **GENERATION OF HUMAN MONOCLONAL-ANTIBODIES BY FUSION OF EBV-ACTIVATED B-CELLS TO A HUMAN MOUSE HYBRIDOMA** *METHODS IN ENZYMOLOGY*
Foug, S. K., Engleman, E. G., GRUMET, F. C.
1986; 121: 168-174
- **PRODUCTION OF HUMAN-ANTIBODIES TO MYCOBACTERIUM-LEPRAE**
Mohaghehpour, N., Cho, S. N., Gelber, R. H., Foug, S. K., Engleman, E. G.
AMER LEPROSY MISSION.1985: 717-18
- **HUMAN MONOCLONAL-ANTIBODIES NEUTRALIZING VARICELLA-ZOSTER VIRUS** *JOURNAL OF INFECTIOUS DISEASES*
Foug, S. K., Perkins, S., KOROPCHAK, C., Fishwild, D. M., Wittek, A. E., Engleman, E. G., GRUMET, F. C., Arvin, A. M.
1985; 152 (2): 280-285
- **PRODUCTION OF HUMAN MONOCLONAL-ANTIBODIES TO MYCOBACTERIUM-LEPRAE**
MOHAGHEHPOUR, N., FOUNG, S. K., GELBER, R. H., BRENNAN, P. J., ENGLEMAN, E. G.
AMER LEPROSY MISSION.1985: 178
- **CONSTITUTIVE PRODUCTION OF B-CELL GROWTH-FACTOR BY HUMAN T-T HYBRIDS DERIVED FROM HELPER T-CELL CLONES**
Trail, P. A., Foug, S. K., Choi, Y. S.
FEDERATION AMER SOC EXP BIOL.1985: 1288-88
- **HUMAN MONOCLONAL-ANTIBODIES AGAINST GROUP-A RED BLOOD-CELLS** *VOX SANGUINIS*
Raubitschek, A., SENYK, G., LARRICK, J., LIZAK, G., Foug, S.
1985; 48 (5): 305-308
- **A NEW APPROACH TO THE DIAGNOSIS OF ACTIVE RH0(D) IMMUNIZATION IN PASSIVELY IMMUNIZED PREGNANT-WOMEN** *VOX SANGUINIS*
Foug, S. K., Perkins, S., MCCALLUM, W. D., Tom, S., Engleman, E. G., GRUMET, F. C.
1985; 49 (3): 206-210
- **RESCUE OF HUMAN MONOCLONAL-ANTIBODY PRODUCTION FROM AN EBV-TRANSFORMED B-CELL LINE BY FUSION TO A HUMAN-MOUSE HYBRIDOMA** *JOURNAL OF IMMUNOLOGICAL METHODS*
Foug, S. K., Perkins, S., Raubitschek, A., LARRICK, J., LIZAK, G., Fishwild, D., Engleman, E. G., GRUMET, F. C.
1984; 70 (1): 83-90
- **GRANULOCYTE DIFFERENTIATION FACTOR PRODUCTION BY HUMAN MARROW AND BLOOD-CELLS**
GREENBERG, P. L., BAKER, S. J., FOK, W. Y., FOUNG, S. K., ENGLEMAN, E. G.
CARDEN JENNINGS PUBL CO LTD.1984: 370
- **ANALYSIS OF VARICELLA-ZOSTER VIRUS WITH HUMAN MONOCLONAL-ANTIBODIES**
Foug, S. K., Engleman, E. G., Perkins, S., KORAPCHAK, C., GRUMET, F. C., Arvin, A.
SLACK INC.1984: A513-A513
- **MONOCLONAL-ANTIBODY (B27M2) SUBDIVIDING HLA-B27** *HUMAN IMMUNOLOGY*
GRUMET, F. C., Fendly, B. M., Fish, L., Foug, S., Engleman, E. G.
1982; 5 (1): 61-72
- **PRODUCTION AND CHARACTERIZATION OF HUMAN T-CELL HYBRIDS PRODUCING INTELEUKIN-2 AND INTERFERON**
FOUNG, S. K., SASAKI, D., ENGLEMAN, E. G.
SLACK INC.1982: A348
- **SUBDIVISION OF B27 BY USE OF A LYMPHOCYTOTOXIC MONOCLONAL-ANTIBODY, B27M2**
GRUMET, F. C., FISH, L., FENDLY, B. M., FOUNG, S., ENGLEMAN, E. G.
ELSEVIER SCIENCE INC.1982: 153
- **PRODUCTION OF FUNCTIONAL HUMAN T-T-HYBRIDOMAS IN SELECTION MEDIUM LACKING AMINOPTERIN AND THYMIDINE** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES*
Foug, S. K., Sasaki, D. T., GRUMET, F. C., Engleman, E. G.
1982; 79 (23): 7484-7488

- **EOSINOPHILIA IN CHILDREN** *PEDIATRIC ANNALS*

Foug, S., Glader, B. E.
1979; 8 (6): 39-?

- **EFFECTS OF STARVATION AND REFEEDING ON MUSCLE PROTEIN-SYNTHESIS AND CATABOLISM IN YOUNG RAT** *JOURNAL OF NUTRITION*

Ogata, E. S., Foug, S. K., Holliday, M. A.
1978; 108 (5): 759-765